SUPPLEMENTARY FIGURES



Supplementary Figure 1. Transfection efficiency of lentivirus miR-22-3p inhibitor and lentivirus miR-22-3p mimic. (A) GFP positive pictures showed the HepG2 cells successfully transfected with lentivirus miR-22-3p inhibitor and lentivirus miR-22-3p mimic. (B) Relative miR-22-3p level in HepG2 cells successfully infected with lentivirus expressing miR-22-3p inhibitor or miR-22-3p mimic. *P<0.05. (C) GFP positive pictures showed the SMMC-7721 cells successfully infected with lentivirus expressing miR-22-3p inhibitor or miR-22-3p mimic. (D) Relative miR-22-3p level in SMMC-7721 cells successfully infected with lentivirus expressing miR-22-3p inhibitor or miR-22-3p mimic. *P<0.05.



Supplementary Figure 2. TET2 is a direct downstream target of miR-22-3p. (A) Binding site of the TET2 3'-UTR and miR-22-3p. (B, C) Dual-luciferase activity of wildtype (WT) and mutant (MUT) TET2 3'-UTR reporter constructs in the presence of miR-22-3p. ***P*< 0.01, ****P*< 0.001. (D) miR-22-3p level in HL-02 cells transfected with miR-22-3p mimic. ***P*< 0.01. (E, F) Protein level of TET2 in HL-02 cells transfected with miR-22-3p mimic. **P*<0.05. (H, I) Protein level of TET2 in HepG2 cells transfected with miR-22-3p inhibitor. **P*<0.05. (H, I) Protein level of TET2 in HepG2 cells transfected with miR-22-3p inhibitor. **P*<0.05. (H, I) Protein level of TET2 in HepG2 cells transfected with miR-22-3p inhibitor. **P*<0.05. (H, I) Protein level of TET2 in HepG2 cells transfected with miR-22-3p inhibitor. **P*<0.05. (H, I) Protein level of TET2 in HepG2 cells transfected with miR-22-3p inhibitor. **P*<0.01.



Supplementary Figure 3. Expression of EMT markers in HCC cells. (A–D) The protein level of TET2 in HCC cells transfected with TET2 CRISPR/Cas9Knockout (KO) and TET2 CRISPR/Cas9Activation (ACT) plasmid. **P*<0.05. (E–H) Expression of EMT related gene protein of HCC cells in control, negative-control, TET2 Knockout (KO) and TET2 Activation (ACT) groups. **P*< 0.05.



Supplementary Figure 4. Co-expression efficiency of lentivirus miR-22-3p inhibitor and TET2 CRISPR/Cas9 KO plasmid. (A) GFP and RFP positive pictures showed the HepG2 cells successfully infected with lentivirus expressing miR-22-3p inhibitor and transfected with TET2 CRISPR/Cas9 KO plasmid. (B, C) Relative TET2 level in HepG2 cells successfully infected with lentivirus expressing miR-22-3p inhibitor and transfected with TET2 CRISPR/Cas9 KO plasmid. (B, C) Relative TET2 level in HepG2 cells successfully infected with lentivirus expressing miR-22-3p inhibitor and transfected with TET2 CRISPR/Cas9 KO plasmid. *P< 0.05. (D) GFP and RFP positive pictures showed the SMMC-7721 cells successfully infected with lentivirus expressing miR-22-3p inhibitor and transfected with TET2 CRISPR/Cas9 KO plasmid. (E, F) Relative TET2 level in SMMC-7721 cells successfully infected with lentivirus expressing miR-22-3p inhibitor and transfected with TET2 CRISPR/Cas9 KO plasmid. *P< 0.05.



Supplementary Figure 5. Working model of β -catenin/miR-22-3p/TET2 axis. Chronic ethanol exposure promotes HCC progression through β -catenin/miR-22-3p/TET2 axis.